9 Meters Biopharma Total Assets | NMTR

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets 9 Meters Biopharma

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
33.1 M	50.2 M	39.2 M	5.3 M	6.45 M	798 K	6.46 M	4.72 M	6.41 M	1.93 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
50.2 M	798 K	15.5 M

Quarterly Total Assets 9 Meters Biopharma

2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
9.31 M	33.1 M	42.1 M	31.5 M	39.3 M	50.2 M	56.7 M	66 M	40.2 M	39.2 M	13.9 M	14.7 M	3.29 M	5.3 M	9.81 M	14.6 M	12.6 M	6.45 M	8.68 M	11 M	13.3 M	798 K	3.39 M	3.55 M	4.42 M	6.46 M	8.59 M	5.92 M	6.46 M	4.72 M	4.72 M	4.72 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
66 M	798 K	18 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
AbbVie ABBV	134 B	$ 263.04	0.49 %	$ 465 B	USA
AbCellera Biologics ABCL	1.36 B	$ 11.41	2.15 %	$ 3.41 B	Canada
Фармсинтез LIFE	2.05 B	-	-	-	Russia
Aclaris Therapeutics ACRS	160 M	$ 5.53	6.02 %	$ 678 M	USA
ADC Therapeutics SA ADCT	323 M	$ 1.09	3.74 %	$ 139 M	Schweiz
Amryt Pharma plc AMYT	816 M	-	-	$ 621 M	Britain
Evelo Biosciences EVLO	64.4 M	-	-14.46 %	$ 27.9 M	USA
Allakos ALLK	96.6 M	-	-	$ 28.6 M	USA
Checkmate Pharmaceuticals CMPI	78.8 M	-	-	$ 231 M	USA
Clovis Oncology CLVS	473 M	-	-7.23 %	$ 13 M	USA
Chimerix CMRX	146 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	165 M	-	-	$ 401 M	USA
ADMA Biologics ADMA	624 M	$ 8.61	0.16 %	$ 2.05 B	USA
Eiger BioPharmaceuticals EIGR	38.8 M	-	-9.21 %	$ 2.55 M	USA
89bio ETNB	479 M	-	-	$ 1.55 B	USA
Freeline Therapeutics Holdings plc FRLN	86.6 M	-	-	$ 384 M	Britain
Fusion Pharmaceuticals FUSN	286 M	-	-	$ 1.41 B	Canada
Guardion Health Sciences GHSI	11.9 M	-	-0.31 %	$ 3.64 M	USA
Genocea Biosciences GNCA	56 M	-	-15.0 %	$ 3.04 M	USA
Gritstone Oncology GRTS	178 M	-	0.42 %	$ 213 M	USA
G1 Therapeutics GTHX	122 M	-	-	$ 370 M	USA
Harpoon Therapeutics HARP	73.7 M	-	-	$ 763 M	USA
Humanigen HGEN	11.2 M	-	-81.12 %	$ 4.28 M	USA
HOOKIPA Pharma HOOK	82.5 M	-	-6.92 %	$ 79.4 M	USA
Intercept Pharmaceuticals ICPT	554 M	-	-	$ 643 M	USA
IGM Biosciences IGMS	266 M	-	-	$ 76.9 M	USA
IMV IMV	31.3 M	-	-	$ 13.1 M	Canada
Intra-Cellular Therapies ITCI	1.37 B	-	-	$ 13.6 B	USA
Kinnate Biopharma KNTE	174 M	-	-	$ 123 M	USA
Chinook Therapeutics KDNY	574 M	-	-	$ 2.6 B	USA
Kaleido Biosciences KLDO	50.1 M	-	-3.69 %	$ 12.4 M	USA
Kronos Bio KRON	124 M	-	1.49 %	$ 50.8 M	USA
Karuna Therapeutics KRTX	1.34 B	-	-	$ 12.2 B	USA
Landos Biopharma LABP	38 M	-	0.58 %	$ 144 M	USA
La Jolla Pharmaceutical Company LJPC	101 M	-	-	$ 154 M	USA
LogicBio Therapeutics LOGC	62.8 M	-	-	$ 229 M	USA
Lumos Pharma LUMO	40.6 M	-	-	$ 35.3 M	USA
Merrimack Pharmaceuticals MACK	19.2 M	-	-	$ 216 M	USA
Stealth BioTherapeutics Corp MITO	50.2 M	-	-	$ 23.9 M	USA
Mirati Therapeutics MRTX	1.2 B	-	-	$ 3.3 B	USA
NexImmune NEXI	8.59 M	-	70.13 %	$ 4.12 M	USA
InVivo Therapeutics Holdings Corp. NVIV	18.8 M	-	-37.48 %	$ 476 K	USA
Nymox Pharmaceutical Corporation NYMX	654 K	-	-19.68 %	$ 18.4 M	Canada
ObsEva SA OBSV	65.4 M	-	-15.52 %	$ 10.5 M	Schweiz
Oncorus ONCR	146 M	-	-8.54 %	$ 3.19 M	USA
OncoSec Medical Incorporated ONCS	21.9 M	-	31.87 %	$ 1.61 M	USA
Oncternal Therapeutics ONCT	36.7 M	-	-24.12 %	$ 1.56 M	USA
Opiant Pharmaceuticals OPNT	70.4 M	-	-	$ 109 M	USA
Orchard Therapeutics plc ORTX	219 M	-	1.02 %	$ 90.8 M	Britain